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The aimed of this study was to determine the implication of the biochemical and the molecular 
mechanism and to describe the properties of an extended-spectrum β-lactamase (ESBL) CTX-M-8 which 
was reported for the first time in Africa. A clinical isolate of Proteus mirabilis FS6449 was isolated from 
a patient hospitalized at an intensive care unit of the Military Hospital in Tunisia in 2009. Antimicrobial 
susceptibility was determined with the disk diffusion method according to Clinical and Laboratory 
Standards Institute (CLSI) guidelines and revealed that this strain was resistant to expanded-spectrum 
β-lactams. Analysis of P. mirabilis FS6449 by double-disk synergy test yielded a positive result 
suggesting the production of ESBLs. Sonicate of the isolate hydrolysed cefotaxime and benzylpenicillin. 
Isoelectric focusing exhibited four β-lactamase bands of isoelectric points (pIs) 5.6, 6, 6.5 and over 7.6. 
Polymerase chain reaction (PCR) and sequencing experiments revealed the presence of four β-
lactamase genes encoding TEM-2, CTX-M-8, TEM-24, and an AmpC enzyme. Among them, the genes 
encoding TEM-24 and an AmpC enzyme were transferred to the recipient by conjugation experiments. 
 





Plasmid-mediated extended-spectrum β-lactamases 
(ESBLs) capable of degrading the expanded-spectrum 
cephalosporins and monobactams are the most important 
resistance determinants emerging worldwide in Entero-
bacteriaceae (Mugnaioli et al., 2006). Since the late 
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Abbreviations: MICs, Minimum inhibitory concentrations; 
CLSI, Clinical and Laboratory Standards Institute. 
ESBLs have emerged in hospital and community settings 
as important sources of urinary tract infections (UTIs) 
(Minarini et al., 2009). CTX-M-type β-lactamases are 
ESBLs and have therefore been classified as the 
functional group 2be of the Bush-Jacoby-Medeiros 
classification scheme (Touati et al., 2006). The CTX-M-
type β-lactamases, encoded by genes that have been 
captured on transferable plasmids from the chromo-
somes of Kluyvera spp., are the most common and 
widespread ESBLs encountered in Enterobacteriaceae 
(Mugnaioli et al., 2006). At present, the CTX-M family 
comprises more than 60 enzymes 
(www.lahey.org/studies/webt.asp) and can be sub-classi-
fied by amino acid sequence similarities into five major 
phylogenetic groups: the CTX-M-1 group including CTX-
M-1, -3, -10, -11, -12, -15, -22, -23, -28, -29, -30, -32, -33, 
-36, -54 and UOE-1; the CTX-M-2 group including CTX-
M-2, -4, -6, -7, -20, -31, -44 (previously Toho-1) and FEC-
1; the CTX-M-8 group including CTX-M-8, -40 and -63; 





-17, -19, -21, -24, -27, -45 (previously Toho-2), -46, -47,-
48,-49 and -50; the CTX-M-25 group with CTX-M-25, -26, 
-39 and -41 (Ben Achour et al., 2009a; Wu et al., 2006; 
Bourouis et al., 2009). The group CTX-M-8 is the rarest 
CTX-M subgroup, with only one previously identified 
member, CTX-M-8 (Bonnet et al., 2000). In Tunisia, the 
prevalence of ESBLs in clinical isolates of Enterobac-
teriaceae varies from 20% (TEM) to 45% (CTX-M) and 
35% (SHV). The SHV-2 enzyme was the first ESBL to be 
isolated, in 1984 from a Klebsiella pneumoniae strain in 
Tunisia. Recently, SHV-12, SHV-2a, CTX-M-3, CTX-M-
27, CTX-M-28, CTX-M-15, CTX-M-16 and CTX-M-9 have 
been described in Tunisians hospitals (Armand-Lefevre 
et al., 2003; Elhani et al., 2010; Bourouis et al., 2009). 
Several reports have detected TEM-type ESBL family 
such as TEM-4, TEM-15, TEM-138 and TEM-164 (Ben 
Achour et al., 2009b). SHV-11 (Ben Achour et al., 2008), 
SHV-104 (EU032604), SHV-28 (Dahmen et al., 2010), 
SHV-27 (Abassi et al., 2008) were recently reported in K. 
pneumoniae which represents one of the most important 
pathogens causing nosocomial infections. 
Moreover, ESBLs have also been reported in 
Escherichia coli strains of food origin including CTX-M-1, 
CTX-M-8, CTX-M-14 and SHV-5 (Jouini et al., 2007). 
Proteus mirabilis causes clinically significant infections 
and is often difficult to eradicate from the host (De 
champs et al., 2000). Various ESBLs, such as TEM-, 
CTX-M-, PER-, and VEB-type ESBLs, have been des-
cribed in P. mirabilis in separate geographic areas (Wu et 
al., 2008). In the present study, we reported the bioche-
mical and the molecular characteristics of a cefotaxime-
resistant P. mirabilis strain which coproduced CTX-M-8-
type ESBL and AmpC β-lactamase for the first time in 
Tunisia and Africa. 
 
 




From June, 2005 to July, 2009, a total of 150 strains of P. mirabilis 
were isolated from patients at the Military Hospital in Tunisia. P. 
mirabilis strain FS6449 was isolated from an intensive care unit on 
May, 2009. The isolate was identified using a Vitek GNI card 
(bioMérieux, Marcy l’Etoile, France). E. coli DH5α (recA1, F
-
, 
endA1, gyrA96, thi-1, hsdR17, rK
-
, mK+, supE44, relA1, DlacU69, 
F80lazDM15) and nalidixic acid resistant E. coli K12 were used 




Antimicrobial susceptibility and synergy testing 
 
Susceptibilities to various antimicrobial agents were tested, and 
potential ESBL-producing isolates were confirmed by the disk 
diffusion method on Mueller-Hinton agar (MH; Diagnostics Pasteur, 
Marcy l’Etoile, France) (Mahrouki et al., 2009). Antibiotic-containing 
disks were purchased from Bio-Rad, Marnes La Coquette, France. 
The double-disk synergy test for confirmation of ESBL activity was 
carried out as described previously (Jarlier et al., 1988), by using 
disks containing amoxicillin-clavulanate (AMX-CA) against cefo-
taxime, ceftriaxone and ceftazidime. The  minimum  inhibitory  con- 




concentrations (MICs) of various β-lactam agents were determined 
by dilution method on MH agar according to Clinical and Laboratory 
Standards Institute guidelines (CLSI, 2007). 
 
 
Analytical isoelectric focusing (IEF) 
 
The ESBL-producing P. mirabilis isolate was subjected to IEF as 
described previously (Bourouis et al., 2010). Crude extracts were 
prepared by sonication, and IEF of the enzyme preparations was 
performed in polyacrylamide gels containing ampholines with a pH 
range of 3 to 10 using a 111 Mini IEF Cell (Bio-Rad). Extracts from 
strains producing TEM-1, TEM-2, TEM-3, and SHV-1 were used as 
standards for pI value of 5.4, 5.6, 6.3, and 7.6, respectively. β-
Lactamases were revealed with the iodine method (Mahrouki et al., 
2009) with benzylpenicillin (0.5 mM) and cefotaxime (3 mM) in 
phosphate buffer (25 mM, pH 7).  
 
 
β -Lactamase assay 
 
Hydrolytic activities of crude extracts for β-lactam antibiotics were 
determined by the spectrophotometric method at the wavelength of 
maximal absorbance for the β-lactam ring of each antibiotic 
(Philippon et al., 1997). The decrease in absorbance of the 
antibiotics at an appropriate concentration was measured in a 
temperature controlled spectrophotometer (Varian R CARY 50 Bio 
UV- visible) at 37°C. Specific activity is calculated on depending of 
Ross and O’Callaghan equation in 1975 (Ross et al., 1975). 
 
 
Polymerase chain reaction (PCR) amplification and DNA 
sequencing 
 
The presence of blaTEM, blaCTX-M and blaAMPC were detected by PCR 
and nucleotide sequencing with appropriated oligonucleotide 
primers (Table 1). Four primer sets were used in reactions with 
plasmid preparations from P. mirabilis FS6449 to amplify blaCTX-M 
sequences and were designated CTX-M-1, CTX-M-2, CTX-M-8 and 
CTX-M-9 (Ben Achour et al., 2009a). Nucleotide and amino acid 
sequence analyses were performed using NCBI analysis tools. The 
resulting sequences were then compared with the reported 




Plasmid DNA isolation and transfer of resistance 
 
Plasmid DNA was extracted from the clinical isolate and 
transconjugant by the alkaline lysis method described by Kado and 
Lui (1981). DNA electrophoresis was performed in 0.8% agarose. 
Gels were stained with ethidium bromide and photographed using 
Polaroid film with a ultraviolet (UV) light source. Transformation 
experiments were carried out by using E. coli DH5α as the 
recipient. Transformants were selected on Luria-Bertani medium 





Conjugation experiments were performed by a liquid mating method 
on Luria-Bertani broth medium as previously described (Ben 
Hamouda et al., 2004). Culture mixtures were incubated overnight 
at 37°C with FS6449 strain as donor and E. coli K12 as the 
recipient at a 1:2 ratio (donor to recipient). Transconjugants were 
selected on Luria-Bertani broth agar plates supplemented by 256 
μg of nalidixic acid and 100 μg of ampicillin per millilitre. The 
resulting transconjugants were subjected to antimicrobials 
susceptibility and isoelectric focusing analysis. 















CTXM-1F 5’ATGGTTAAAAAATCACTGCGTC 3’ 
60 864 
CTXM-1R 5’TTGGTGACGATTTTAGCCGC 3’ 
CTX-M-2 group 









CTXM-9F 5’ATGGTGACAAAGAGAGTGCAA 3’ 
60 876 
CTXM-9R 5’TCACAGCCCTTCGGCGATGATTCTCGC 3’ 
AmpC 
AmpC 1 5’ATGATGAAAAAATCGTTATGC 3’ 
64 1,143 




Table 2. MICs of various antimicrobial agents obtained for the clinical isolate P. mirabilis FS6449, transformants, transconjugants 




P. mirabilis FS6449 E. coli K12× pFS6449 E. coli K12 E. coli DH5α/pFS FS6449 E. coli DH5α 
Ampicillin  >512 512 8 512 8 
Ticarcilline >512 >512 8 >512 2 
cephalothin >512 512 <2 512 2 
Cefoxitin  32 128 2 64 4 
Cefotaxime  512 512 <2 512 <2 
Ceftriaxone  512 512 <2 512 <2 
Ceftazidime  >512 512 <2 512 <2 
Aztreonam  256 128 <2 64 <2 
Nalidixic acid  64 >512 512 8 <2 
Ciprofloxacin 4 4 2 4 <2 
Chloramphenicol  256 8 <2 8 2 
Tetracycline  128 8 <2 4 <2 
Oflaxacin 256 4 2 2 <2 
Streptomycin 512 256 2 256 <2 






P. mirabilis FS6449 was isolated in 6 May, 2009 from a 
blood specimen of an inpatient. Antimicrobial suscep-
tibility testing showed that this isolate presented a multi-
drug resistance phenotype including resistance to the 
extended-spectrum β-lactams (Table 2). The double-disk 
synergy tests showed positive results for the wild strain, 
its transformants and transconjugants, suggesting the 
presence of a class A ESBL. The isolate exhibited a high 
level resistance not only to cefotaxime (MIC, 512 mg/L), 
ceftazidime (>MIC, 512 mg/L), and aztreonam (MIC, 512 
mg/L) but also to cefoxitin (MIC, 32 mg/L). The strain was 
also resistant to tetracycline, chloramphenicol, amikacin, 
gentamycin, and streptomycin (Table 2). Similar results 
were observed with the transformant and transconjugant 
except for chloramphenicol and tetracycline. Analytical 
isoelectric focusing with benzylpenicillin as substrate of 
crude β-lactamases extract of P. mirabilis FS6449 
revealed that this strain produces four β-lactamases with 
pIs of 5.6, 6, 6.5 and over 7.6. Only the β-lactamases of 
pI 6.5 and over 7.6 were detected on the crude β-
lactamases extract of transformant and transconjugant. 
The resistance to expanded-spectrum cephalosporins 
was successfully transferred to a recipient strains, E. coli 
K12 with the frequency of transfer equivalent to 7.2 × 10
-2
 
transconjugant/recipient and E. coli DH5α. This 
resistance was confirmed by the MICs (Table 2). The 
results of plasmid analysis showed that the transcon-
jugant and the transformant have similar profiles com-
pared-to-the-parental strain. PCR- and-sequencing 





Table 3. Specific activities -lactamases of P. mirabilis strain 


















genes showed the detection of CTX-M-8 and TEM-2 and 
confirmed the presence of TEM-24 in parental strain 
FS6449 and its transconjugant E. coli K12× pFS6449 and 
transformant E. coli DH5α/pFS FS6449. The PCR with 
the consensus primers of Citrobacter freundii ampC 
family as previously described (Winkor et al., 2001) was 
positive in parental strain and the transconjugants and 
electroporant which show the coproduction of a plasmid-
mediated AmpC type cephalosporinase with the CTX-M-
8. FS6449 P. mirabilis strain have showed a high level of 
hydrolytic activity to benzypenicillin and ticarcillin, com-
parable to that observed for the extended-spectrum ce-
phalosporins and the specific activity ranged from 0.20 to 
6.95 U/mg of protein. The specific activity values of 
cephalosporin indicated that cefotaxime is more efficiently 





Plasmid-encoded ESBLs impair the efficacy of expanded-
spectrum cephalosporins and monobactams and are 
among the most important acquired resistance 
determinants emerging worldwide in members of the 
Enterobacteriaceae (Bradford, 2001; Paterson and 
Bonomo, 2005; Bonnet, 2004). In recent years CTX-M 
enzymes have become the most widespread ESBLs and 
they confer a high level resistance to cefotaxime but have 
a low level activity towards ceftazidime (Canton and 
Coque, 2006; Eckert et al., 2004). In Tunisia the 
frequency of acquired resistance to broad-spectrum 
cephalosporins seemed to be increasing the last years. In 
the region of Sfax (Tunisia), the overall frequency of 
resistance increased from 10% in 1999 to 18% in 2005 
(Mkaour et al., 2008). This increase was statistically 
significant. High prevalence rates of third generation 
cephalosporins resistance have been observed in 
intensive care units (48%), hematology  and oncology wards 




wards (27%) and pediatric wards (25%) (Mkaour et al., 
2008). In the present study, we describe the presence of 
a CTX-M-8-type ESBL coproduced with a plasmid-me-
diated AmpC β-lactamase in a clinical isolate for the first 
time in Tunisia.  
The phenotypic study via the suscep-tibility test and the 
minimum inhibitory concentration determination showed 
that P. mirabilis FS6449 is a multi-drug resistant isolate 
and that the transformant and the transconjugant had the 
same levels of resistance almost. PCR and Isoelectric 
focusing of strain FS6449 with benzylpenicillin as 
substrate revealed the presence of four β-lactamases 
with approximate pI of 5.6; 6; 6.5 and superior than 7.6 
which matched respectively to TEM-2, CTX-M-8, TEM-24 
and AMPC.  
These β-lactamases were active against benzypenicillin 
and having a level hydro-lytic activity to extended 
spectrum cephalosporin parti-cularly cefotaxime and 
ceftriaxone (Table 3). Only β-lactamases with pI of 6.5 
and superior than 7.6 were detected on the crude 
enzyme extract of transformant of P. mirabilis FS6449 
isolate. This finding indicates that the genetic determinant 
of CTX-M-8 and TEM-2 may be located on plausible 
chromosome. Sequencing experi-ments showed that the 
blaCTX-M gene encoding for CTX-M type β-lactamase was 
identical to the blaCTX-M-8.  
Few research reports the presence of CTX-M-8 
subgroups in Tunisia and the extended-spectrum β-
lactamase CTX-M-8 was isolated for the first time in E. 
coli strains of food (chicken) origin. The strain was 
isolated in 2006 and the phenotypic study showed a high 
level resistance to tetracycline and nalidixic acid (Jouini 
et al., 2007). In Tunisia, CMY-4, an AmpC-type plasmid-
mediated β-lactamase was the first  β-lactamase 
described in clinical isolate of P. mirabilis in January 1996 
at Charles Nicole Hospital in Tunis (Verdet et al., 1998) 
and in 1999, a novel ACC-1, a plasmid-encoded 
cephalosporinase ACC-1 was identified in clinical isolate 
of P. mirabilis at CHU Habib Bourguiba Hospital in Sfax 
(Rhimi-Mahjoubi et al., 2002).  
The susceptibility testing to cefoxitin show the high 
level of resistance to the E. coli transconjugants and the 
transformants compared with the parental strain (Table 
2). IEF and PCR experiments show that this resistance 
was due to the production of the plasmid-encoded 
cephalosporinase which was detected on pI superior than 
7.6. This proves the association of hyperproduction of a 
plasmidic AmpC with CTX-M-8 which exhibit notable 
activity against ceftazidime, cefotaxime and cefoxitin. The 
gene blaAMPC was transferred with blaTEM-24 by conjugation 
and transformation experiments and they were located on 
the same large plasmid.  
In conclusion, the presence of strains producing CTX-M 
genes with an association of a plasmidic AmpC in the 
hospital environment could be linked to insufficient 
measures in room's surface cleaning, so continued 
surveillance is essential to control the spread of this 
resistance. 
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